Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUTH: Dasatinib + quercetin for fibrotic NAFLD/MASLD
2024-517593-21-00Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing Dasatinib + quercetin with Placebo (2 arms). Primary endpoint: Histologic fibrosis improvement without worsening of NAFLD score. Started Oct 2024; status: completed.
02
Drugs
dasatinibquercetin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2024-517593-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517593-21-00.